Fundz

bit.bio

Cambridge, England, United Kingdom · Financial Services, Information Technology, Payments

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at a

Key facts

Headquarters
Cambridge, England, United Kingdom
Employees
162
Industries
Financial Services, Information Technology, Payments
Status
Private
Website
www.bit.bio
LinkedIn
Company page

Recent activity at bit.bio

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

bit.bio funding history

DateRoundAmount
Nov 2026Series D$25.0M
Jan 2026Funding Round$50.0M
Nov 2021Series BUndisclosed

Leadership

  • Sejla Salic-Hainzl, Chief Technology Officer
  • Connie O'Donnell, Director of Marketing
  • Abbey Crawford, Marketing Operations Manager
  • Przemek Obloj, Chief Executive Officer

Verified email and direct lines for bit.bio’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

bit.bio files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

bit.bio in the news

Companies similar to bit.bio

  • Token.io · Financial Services, Information Technology, Payments, Software
  • Helios · Financial Services, Information Technology, Payments, Software
  • Nucleus Security · Financial Services, Information Technology, Payments, Software
  • Cloud Walk · Financial Services, Information Technology, Payments, Software
  • AllPaid · Financial Services, Information Technology, Payments, Software

About bit.bio: questions and answers

What does bit.bio do?

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at a

Where is bit.bio headquartered?

bit.bio is headquartered in Cambridge, England, United Kingdom.

How many employees does bit.bio have?

bit.bio has about 162 employees.

Has bit.bio raised funding?

Yes. Fundz has recorded 3 funding events for bit.bio. The most recent, Series D of $25.0M, was in Nov 2026.

Who leads bit.bio?

Przemek Obloj is a Chief Executive Officer at bit.bio.

What is the latest news on bit.bio?

On Nov 4, 2026, Human cell programming company bit.bio closes $25M Series D funding to enhance its cell models and increase technology access. The investment includes support from M&G Investments and Dr Jonathan Milner.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches bit.bio across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.